# A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

> **NCT05456867** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 250 (estimated)

## Conditions studied

- NSCLC, Non-small-cell Lung Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05456867
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-31
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456867, "A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05456867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*